INTRODUCTION: The development of an accepted clinical definition, classification system and validated outcome questionnaire for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has led to a flurry of clinical trial activity over the last 15 years. METHODS:Twenty-four of these studies enrolled a homogeneous population of CP/CPPS patients, were prospective randomized placebo or sham controlled, and employed the National Institutes of Health chronic prostatitis symptom index (CPSI) as an outcome parameter. RESULTS: This review of the evidence and clinical impact from these studies suggests that physician's strict adherence to a rigid evidence-based approach for the treatment of a CP/CPPS patient will result in disappointed patients as well as disappointed physicians. CONCLUSIONS: There is no one particular treatment that shows significant clinical efficacy to be recommended as a mono-therapy for CP/CPPS. Therefore, the physician must adapt his knowledge and interpretation of the evidence from randomized placebo- and sham-controlled trials to determine what therapy or therapies are best indicated for each individual patient.
RCT Entities:
INTRODUCTION: The development of an accepted clinical definition, classification system and validated outcome questionnaire for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has led to a flurry of clinical trial activity over the last 15 years. METHODS: Twenty-four of these studies enrolled a homogeneous population of CP/CPPSpatients, were prospective randomized placebo or sham controlled, and employed the National Institutes of Health chronic prostatitis symptom index (CPSI) as an outcome parameter. RESULTS: This review of the evidence and clinical impact from these studies suggests that physician's strict adherence to a rigid evidence-based approach for the treatment of a CP/CPPSpatient will result in disappointed patients as well as disappointed physicians. CONCLUSIONS: There is no one particular treatment that shows significant clinical efficacy to be recommended as a mono-therapy for CP/CPPS. Therefore, the physician must adapt his knowledge and interpretation of the evidence from randomized placebo- and sham-controlled trials to determine what therapy or therapies are best indicated for each individual patient.
Authors: Sylvia M Bates; Valerie A Hill; John B Anderson; Christopher R Chapple; Rosemary Spence; Claire Ryan; Martin D Talbot Journal: BJU Int Date: 2007-02 Impact factor: 5.588
Authors: J Curtis Nickel; Joe Downey; Janet Clark; Richard W Casey; Peter J Pommerville; Jack Barkin; Gary Steinhoff; Gerald Brock; Allan B Patrick; Stanley Flax; Bernard Goldfarb; Bruce W Palmer; Joseph Zadra Journal: Urology Date: 2003-10 Impact factor: 2.649
Authors: Dean A Tripp; J Curtis Nickel; Laura Katz; Adrijana Krsmanovic; Mark A Ware; Darcy Santor Journal: Can Urol Assoc J Date: 2014-11 Impact factor: 1.862
Authors: Ivan Urits; Ruben Schwartz; Harish Bangalore Siddaiah; Sathyadev Kikkeri; David Chernobylsky; Karina Charipova; Jai Won Jung; Farnad Imani; Mohsen Khorramian; Giustino Varrassi; Elyse M Cornett; Alan David Kaye; Omar Viswanath Journal: Anesth Pain Med Date: 2021-02-16